Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Tekmira Comments on Market Activity

Abstract:
Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX:TKM) announced today that Market Regulation Services, on behalf of the Toronto Stock Exchange, has requested the Company comment on the recent activity in the shares of Tekmira. There are no new corporate developments at the Company.

Tekmira Comments on Market Activity

VANCOUVER, BC | Posted on July 9th, 2007

The Company, however, notes that one of its partners, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced today that it entered into a major alliance with Roche that highlights Alnylam's leadership position in the discovery and development of RNA interference (RNAi) therapeutics. The Alnylam announcement can be accessed from the Alnylam website at www.alnylam.com. Tekmira and Alnylam announced on January 9, 2007 the signing of a strategic alliance whereby Alnylam gained access to Tekmira's liposomal delivery formulation technology through a worldwide exclusive license for the discovery, development, and commercialization of RNAi therapeutics.

Liposomal and/or lipid nanoparticle formulations are important technologies for systemic delivery of RNAi therapeutics. Tekmira's intellectual property estate is comprised of certain key, issued patents, such as those derived from the Wheeler and Semple patent series (U.S. Patent Nos. 5,976,567, 6,815,432, and 6,858,225), that are considered important for the development and commercialization of liposomal and/or lipid nanoparticle formulations of oligonucleotide therapeutics, including small interfering RNAs (siRNAs), the molecules that mediate RNAi.

####

About Tekmira Comments on Market Activity
Tekmira Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. Further information about Tekmira and this news release can be found at www.tekmirapharm.com.

Forward Looking Statements

There are forward-looking statements and information contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions, and the negative of such expressions. Such forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements and information. Such factors include, among others, Tekmira's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Tekmira's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements or information. Tekmira disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements or information contained herein to reflect future results, events or developments, except as required by law.

The common shares of Tekmira are traded on the Toronto Stock Exchange under the trading symbol "TKM".

For more information, please click here

Contacts:
Tekmira Pharmaceuticals Corporation - Investors
Ian Mortimer
Senior Vice President, Finance and Chief Financial Officer
(604) 419-3200
or
James Hoggan & Associates Inc. - Media
Nicole Rizgalla
(604) 742-4268

Copyright © Market Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018

Nanometrics to Present at the 30th Annual ROTH Conference February 27th, 2018

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018

Nanowire LED Innovator Aledia Announces €30 ($36M) Million Series-C Financing: Intel Capital Joins Existing Investors to Commercialize Certain Nanowire-LED Technologies for Mobile Displays January 29th, 2018

Nanomedicine

JPK reports on research of the Mestroni Lab at the University of Colorado Denver which use the JPK NanoWizard® AFM to help in the characterization of cardiomyopathies April 24th, 2018

Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018

Observing biological nanotransporters: Chemistry April 19th, 2018

Nanobiotix Shows NBTXR3 Nanoparticles Can Stoke Anti-Tumor Immune Response April 17th, 2018

Announcements

JPK reports on research of the Mestroni Lab at the University of Colorado Denver which use the JPK NanoWizard® AFM to help in the characterization of cardiomyopathies April 24th, 2018

Organic solar cells reach record efficiency, benchmark for commercialization April 23rd, 2018

Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018

New qubit now works without breaks: A universal design for superconducting qubits has been created April 19th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project